Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study tested a new treatment combination for people with advanced endometrial cancer or uterine sarcoma who had not yet received other treatments. It combined an immunotherapy drug (TQB2450) and chemotherapy, with or without a targeted therapy pill (anlotinib). The goal was …

This early-stage trial tested a new combination of oral and injectable drugs for people with advanced HR-positive, HER2-negative breast cancer that had worsened after hormone therapy. The main goals were to find the safest and most effective dose of the new drug TQB3912 when give…

This study tested an oral capsule called TQB3616 against a placebo in adults with advanced dedifferentiated liposarcoma, a rare and aggressive cancer. The main goal was to see if the drug could delay cancer growth or extend life. The trial was stopped early after enrolling 26 of …

This early-stage study tested a new two-drug combination (TQB2223 and penpulimab) for people with advanced liver cancer that had spread. The main goal was to check the safety and initial signs of effectiveness of this treatment. The study was terminated after enrolling 22 partici…

This study tested a combination of two oral drugs, TQ05105 and TQB3909, for adults with moderate-to-high risk myelofibrosis, a serious bone marrow cancer. The main goals were to find a safe dose and see if the treatment could reduce spleen size and ease symptoms. The trial was te…